Portfolio

Oxford BioTherapeutics

Oxford Biotherapeutics is a leading drug discovery business, focussed on the development of targeted antibody-based medicines for oncology. The company has developed an exciting portfolio of drugs, which following pre-clinical testing are now progressing into clinical testing. The company has collaborations with a number of major life science groups, including Menarini, Seattle Genetics and Boehringer Ingelheim.

Oxford BioTherapeutics

Anaxsys Technology is a medical diagnostic company, developing an exciting family of devices based on its highly novel sensor platform. The lead device, a respiratory rate monitor for use in primary care, is already approved for sale within the EU and India and regulatory approvals are currently underway in other markets. Other devices in advanced development include the diagnosis and monitoring of asthma and chronic obstructive pulmonary disease and the early identification of lung cancer.

Oxford BioTherapeutics

River Marketing is a leading performance improvement agency, delivering bespoke employee reward & recognition and incentive programmes for companies and their stakeholders. Since completion of our investment, the company has continued to grow rapidly. The business has also completed the acquisition of a data systems business, which has enabled the team to expand its range of services to clients to include business intelligence services.

Oxford BioTherapeutics

Elucigene Diagnostics produces a range of assays for cystic fibrosis testing and prenatal analysis of common chromosome abnormalities, such as Down Syndrome. The company designs and produces all products from their world class research and manufacturing facility in Manchester. The assays are used by leading laboratories around the world.

Oxford BioTherapeutics

Development capital for a leading designer and manufacturer of energy-efficient lighting and industrial controls for the commercial sector. The investment has allowed improvements in the manufacturing and sourcing operations, together with providing additional working capital to facilitate the continued rapid growth of the business.

Oxford BioTherapeutics

BEST has developed a leading energy monitoring solution, which enables major companies and organisations to substantially reduce their energy consumption. As well as leading to significant cost savings, the solution also helps clients fulfil their commitment towards environmental sustainability. We invested growth capital into the company to enable the team to accelerate deployment of their solution across their blue-chip clients and distribution network.

Oxford BioTherapeutics

International Logistics Group Limited is a leading provider of fulfilment and global delivery services. With state of the art technology and processes, the company helps over 700 clients worldwide meet the needs of their own customers. We backed the incumbent management team to acquire the business, with a strong plan to further accelerate the growth of the business.

Oxford BioTherapeutics

Dimensional Imaging provides state-of-the-art facial performance capture software and solutions for use in the film and computer games industries. Already in use by several major studios, the technology is achieving rapid adoption in leading games and film titles. We invested growth capital into the business, so that it may further expand its operations, particularly in North America.

Oxford BioTherapeutics

Grace Personnel is a leading independent provider of recruitment services within the Thames Valley. We acquired the business from the founder, who wished to exit the business for personal reasons. We provided a full package of debt and equity to complete the acquisition quickly, together with additional working capital.

Oxford BioTherapeutics

Suresense creates energy efficient technologies for deployment into the energy intensive industrial sector. Their range of advanced lighting solutions and industrial motor controllers are used by leading blue-chip clients across the world, with a particular emphasis on the plastics, recycling and automotive sectors. As well as helping fund the acquisition, we also provided growth capital to accelerate development of the business.

Oxford BioTherapeutics

Redkite is a financial surveillance software business developed by two former JP Morgan executives. Sales were achieved with a number of investment banks, including HSBC Global Markets, Renaissance Capital, State Street Securities and Jeffries International. The business was sold in October 2012 for an undisclosed initial consideration and further potential payments subject to certain criteria.

Oxford BioTherapeutics

Future Route is the developer of Validis, a software tool designed to provide financial institutions and accounting firms quick and secure access to their clients data. Validis then validates and standardises this data allowing institutions to generate and output both summarised and detailed reports in precise formats which can be tailored to their needs. Customers include Deloittes and Bibby Financial Services.

Oxford BioTherapeutics

White Cross Vets is a fast growing chain of veterinary practices based in the Midlands and North of England. With eight practices already in operation prior to our investment, the team had already proven their concept and business model. With our support the team have been able to accelerate the rollout of the concept, with the size of the business doubling in the two years subsequent to investment.

Oxford BioTherapeutics

MBI of the UK’s largest independent bathroom and kitchen distributor. We provided a flexible package of debt and equity to complete the acquisition and fund substantial investment into the business with a view to further increasing operational efficiencies and allowing significant growth.